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ess: yhasega@med.nagoSummary Although pulmonary toxicity associated with gefitinib, an epidermal
growth factor receptor inhibitor, has been reported recently, the accumulation of
clinical information and the underlying mechanisms of gefitinib-induced interstitial
lung disease (ILD) remain insufficient and unclear. After retrospectively reviewing
the clinical records and chest X-rays of 489 lung cancer patients who were treated
with gefitinib, we diagnosed four cases of gefitinib-induced ILD who underwent
fiberoptic bronchoscopy and bronchoalveolar lavage (BAL). We found that the period
of time from starting gefitinib to the onset of ILD was short, and concluded that a
careful and close observation of a chest imaging study and a collection of respiratory
symptoms was recommended. All four patients were treated with a high dose of
corticosteroids, and ILD was resolved. We detected high levels of interferon-
inducible protein-10 in BAL fluid, although we could not demonstrate the
characteristic features of laboratory findings or BAL fluid cell analysis. We
speculated that a Th1 type of lung tissue inflammation or lung injury might be
involved as a part of mechanisms underlying gefitinib-induced ILD.
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Gefitinib (Iressa, AstraZeneca, Osaka, Japan), an
epidermal growth factor receptor (EGFR) inhibitor,
is a new molecular-targeted agent for the treat-
ment of patients with advanced non-small-cell lung
cancer (NSCLC) who fail to respond to chemother-
apy. It has novel pharmacological mechanisms that
affect cancer by targeting the inhibition of EGFR
tyrosine kinase. Several clinical studies suggest
that the drug is well tolerated and expected to
possess fairly effective antitumor activity, espe-
cially for patients with EGFR mutations.1–5 Gefitinib
was approved on July 5, 2002 in Japan for the
treatment of patients with advanced NSCLC pre-
viously treated with chemotherapy. The most
commonly reported toxicities associated with this
drug were mild and self-limiting such as eczema
and diarrhea.6 Although gefitinib was recognized as
a relatively safe oral anti-cancer agent, pulmonary
toxicity (interstitial lung disease; ILD) associated
with gefitinib has been reported as a serious
adverse effect.7–9 The incidence of gefitinib-in-
duced ILD was reported to be 3.2% and 6.8%,
respectively, in Japan.10,11 A multicenter prospec-
tive review reported 215 out of 3222 cases of
gefitinib-induced ILD (5.81%), 83 of whom (38.6%)
died of ILD.12 However, the mechanisms of gefiti-
nib-induced ILD remain unknown, and no clinical/
physiological analysis has been reported. We report
here four cases of ILD induced by gefitinib who
underwent bronchoscopy and pulmonary function
tests. We obtained and analyzed bronchoalveolar
lavage (BAL) fluid from all four. These data will
provide the clinical and biological information
needed to enhance our understanding of gefitinib-
induced ILD.Patients and methods
Patients
We retrospectively reviewed the clinical records
and chest X-rays of 489 lung cancer patients who
were treated with gefitinib from August 2002 to
September 2003. The review was performed at a
meeting for the evaluation of gefitinib-induced ILD,
and the diagnosis was made by the consensus of
several chest physicians and one radiologist who
was an expert in chest radiology. We defined
gefitinib-induced ILD as an acute pulmonary syn-
drome with diffuse pulmonary infiltrates and with-
out evidence of other pathologies such as infectious
diseases, systemic inflammatory response syn-drome, lymphangitis carcinomatosis, radiation
pneumonitis, or pre-existing collagen-vascular dis-
ease. The infectious etiology of the respiratory
disease was based on the microbiological evalua-
tions, including BAL fluid culture, blood culture,
cytomegalovirus antigen test, urine antigen test for
Legionella pneumophila, polymerase chain reac-
tion DNA test for Pneumocystis carinii, and paired
sera (4–6-week intervals) for subsequent serology
tests (chlamydia, mycoplasma, and respiratory
viruses). According to the above-mentioned criter-
ia, we diagnosed four cases of gefitinib-induced ILD
who underwent fiberoptic bronchoscopy and BAL.
We collected their clinical information (patient
age, gender, smoking status, histological diagnosis
of lung cancer, prior chemotherapy, duration of
gefitinib treatment, laboratory data, and pulmon-
ary function tests).Bronchoalveolar lavage
BAL was performed with three (50mL each)
aliquots of sterile saline solution followed by
manual aspiration using a flexible bronchoscopy.
The aspirates of three consecutive aliquots were
pooled, and centrifuged to separate fluid from the
cells. Fluid was stored at 80 1C until conducting
measurements of interferon-inducible protein-10
(IP-10) and thymus- and activation-regulated che-
mokine (TARC) concentrations. Cell differentials
were obtained on cytospin preparations, using a
Diff-QuikTM stain (Scientific Products, McGraw Park,
IL). As for the analysis of cell surface markers,
fluorescein isothiocyanate conjugated CD4 and CD8
monoclonal antibodies (Ortho Diagnostics Inc.,
Raritan, NJ) were used, and loaded on flow
cytometry.
Concentrations of IP-10 and TARC were evaluated
by enzyme-linked immunosorbent assay with
matched antibody pairs (R&D Systems Inc., Min-
neapolis, MN) according to the manufacturer’s
recommendations. Briefly, samples were added to
microtiter plates precoated with murine monoclo-
nal antibody to IP-10 or TARC first antibody.
Horseradish peroxidase-conjugated anti-IP-10 or
anti-TARC second monoclonal antibody (which
recognizes a different epitope from the first anti-
body,) was then added. After being incubated for
2 h, the plates were washed six times and a
substrate solution (tetramethylbenzidine) was
added. After color development was stopped, the
optical density was measured with a microplate
reader (EAR 400AT; SLT-Labinstruments, Salzburg,
Austria) at a 450-nm wavelength. Recombinant
chemokines (R&D Systems Inc., Minneapolis, MN)
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standard curves.Pulmonary function tests and radiographic
examination
Pulmonary function was measured by standard
techniques according to the method described in
the American Thoracic Society 1994 update, using a
CHESTAC-55V (Chest, Tokyo, Japan) package. Pul-
monary function tests included forced vital capa-
city (FVC), forced expiratory volume in 1 s (FEV1),
and diffusing lung capacity for carbon monoxide
(DLCO) and arterial blood gases. The DLCO was
measured using the single-breath technique. The
predicted values for FEV1, FVC and DLCO were
calculated according to the proposal of the
Japanese Respiratory Society. HRCT scanning was
performed using an X-Vigor Real (Toshiba, Tokyo,
Japan) CT scanner. Slices of 1mm were taken at 10-
mm intervals throughout the thorax, while patients
held their breath at full inspiration in the supine
position. HRCT was performed at the onset of ILD
and prior to discharge.Laboratory examination
Peripheral white blood cells and the level of serum
C-reactive protein (CRP), lactate dehydrogenase
(LDH), Krebs von den Lungen-6 (KL-6), and surfac-
tant protein-D (SP-D) were measured at the onset
of ILD. Both peripheral blood and BAL fluid
lymphocytes stimulating tests (DLST) with gefitinib
were performed. Lymphocytes (1 106 cells/mL)
were separated from heparinized blood or BAL
fluid, and incubated with varying concentrations of
gefitinib at 37 1C for 72 h. Then, lymphocyte
proliferation was assayed by incubation with
[3H]tymidine for 16 h. Stimulation indices were
calculated from the ratio of radioactivity in the
lymphocytes stimulated with and without gefitinib.Table 1 Patients characteristics.
Patient Sex Age Smoking PY PS Histolo
(No) (years)
1 M 73 Ex 40 1 Ad
2 M 71 Ex 46 1 Sq
3 M 55 Cu 30 0 Ad
4 M 68 Ex 48 1 Ad
PY, pack-years smoked; Ex, ex-smoker; Cu, current smoker; PS, E
lung cancer (Ad, adenocarcinoma; Sq, squamous cell carcinoma
Onset, period of time from starting gefitinib to developing intersA stimulation index of 200% or more was considered
positive for DLST.Results
Patients characteristics
All four patients were males with a mean age of
66.8 years (range 55–73). Patients were with ECOG
performance status 0–1 and stage IV non-small-cell
carcinoma (adenocarcinoma three, squamous cell
carcinoma one). Three patients were ex-smokers
and one was a current smoker. All patients had
previously undergone chemotherapy with carbopla-
tin plus paclitaxel or gemcitabine, and none had
received radiation therapy. None of them had
habitual intake of herbs, special plants or folk
medicine. Patients visited the hospital complaining
of dyspnea (4/4), dry cough (3/4), and cyanosis (1/
4) after the start of gefitinib. Their median length
of treatment with gefitinib was 15 days. Patient
characteristics are shown in Table 1.
Radiological examination
Chest radiography demonstrated diffuse infiltrates
in both lung fields (Fig. 1A). HRCT of the chest
showed bilateral diffuse ground-glass infiltrates
(4/4) (Fig. 1B), honeycombing (1/4), emphysema
(1/4), and some areas of patchy consolidation (3/
4). The bilateral diffuse ground-glass infiltrates and
patchy consolidation were resolved on the discon-
tinuation of gefitinib and treatment with corticos-
teroid.
Laboratory findings and pulmonary function
tests
White blood cell counts in peripheral blood and
serum LDH levels increased only in one patientgy Stage Prior chemotherapy Onset (days)
1st 2nd
IV CBDCA+PTX — 15
IV CBDCA+GEM — 14
IV CBDCA+PTX — 27
IV CBDCA+PTX GEM 15
COG performance status; Histology, histological diagnosis of
); CBDCA, carboplatin; PTX, paclitaxel; GEM, gemcitabine;
titial pneumonia.
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CRP (4/4), SP-D (2/4) and KL-6 (3/4) were
observed. DLST with gefitinib was performed using
peripheral blood. They were negative in all
patients’ samples (Table 2). Pulmonary function
tests revealed restrictive impairment in all pa-
tients. Arterial blood oxygenation and DLCO wereFigure 1 Chest X-ray (A) and high-resolution computed
tomography (B) of case 2. Diffuse ground-glass opacities
are seen in both lung fields.
Table 2 Laboratory data.
Patient (No) WBC (/mm3) LDH (IU/L) CRP (mg
1 23,500 1549 23.7
2 7000 259 6.2
3 6600 252 5.2
4 7000 198 3.4
WBC, white blood cells; CRP, C-reactive protein (o0.3); LDH, la
(o500); SP-D, surfactant protein D (o110); DLST, drug lymphocyreduced (mean oxygen tension in arterial blood;
55.5 Torr, mean DLCO 48.3%) (Table 3).Bronchoalveolar lavage fluid analysis
BAL fluid was obtained from all four patients.
Pulmonary pathogens did not grow in BAL fluid
quantitative cultures, including bacterial, fungal,
and viral cultures. Polymerase chain reaction was
negative for cytomegalovirus, mycobacteria, and P.
carinii. Malignant cells were not detected in all BAL
fluid. An increase of total cell counts in BAL fluid
was observed in two patients (no. 2 and no. 4 in
Table 4). A predominance of lymphocytosis was
observed in patient no. 4, and of eosinophils in
patient no. 2. The CD4:CD8 ratio varied among the
patients. DLST with gefitinib was performed using
BAL fluid lymphocytes in all patients, with negative
results in all samples. Upon measuring concentra-
tions of IP-10 and TARC in BAL fluid, we detected
high levels of IP-10 in the fluid of all our patients. In
contrast, for comparative data we measured the
concentration of IP-10 in BAL fluid from eight
patients with pathologically diagnosed usual inter-
stitial pneumonia (UIP). We could detect no IP-10 in
BAL fluid from four patients out of eight with UIP,
while the remaining four showed levels below
400 pg/mL of IP-10. On the other hand, one case
(patient 3) showed an elevation of TARC in BAL
fluid. As a control, we measured the concentration
of TARC in BAL fluid from eight patients with UIP,
and could not detect TARC in the fluid from five of
them, while the remaining three showed levels
below 10 pg/mL of TARC.Treatment and prognosis
After diagnosis of ILD, all four patients stopped
taking gefitinib and were treated with high-dose
corticosteroids (2mg/kg/day up to 1 g/day of
intravenous methylprednisolone). After starting
corticosteroid therapy, oxygenation and interstitial
shadows began to improve gradually in all patients.
Corticosteroids were thereafter reduced to a/dL) SP-D (ng/mL) KL-6 (U/mL) DLST
620 2230 Negative
380 1010 Negative
45 261 Negative
115 662 Negative
ctate dehydrogenase (o250); KL-6, Krebs von den Lungen-6
te stimulating test.
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Table 3 Pulmonary function tests.
Patient (No) FVC (%pred.) FEV1 (%pred.) FEV1/FVC (ratio) DLCO (%pred.) PaO2 (Torr) PaCO2 (Torr)
1 64.5 80.2 87.9 41.7 40.5 33.0
2 57.7 57.8 69.8 41.4 58.7 34.1
3 66.7 75.9 87.0 61.6 66.6 39.6
4 61.5 69.5 87.7 48.6 56.2 34.8
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; DLCO, diffusion of carbon monoxide; %pred, %predicted
normal; PaO2, oxygen tension in arterial blood in room air; PaCO2, carbon dioxide tension in arterial blood in room air.
Table 4 Analysis of bronchoalveolar lavage fluid.
Patient
(No)
Total cell count
( 103/mL)
Mac
(%)
Lymph
(%)
Neut
(%)
Eosin
(%)
CD4:CD8
(ratio)
Alb
(mg/dL)
IP-10
(pg/mL)
TARC
(pg/mL)
1 170 78.7 14.3 6.9 0.1 4.3 56.0 12849.0 0.0
2 376 71.7 17.1 1.4 10.3 NA 35.5 3274.5 0.0
3 166 86.3 13.0 0.7 0.0 NA 156.0 4944.5 53.0
4 650 37.0 62.0 1.0 0.0 1.5 47.4 2579.7 0.0
Mac, macrophages; Lymph, lymphocytes; Neut, neutrophils; Eosin, eosinophil; Alb, albumin; IP-10, interferon inducible protein
10; TARC, thymus and activation-regulated chemokine; NA, not applicable.
K. Kataoka et al.702maintenance dose (20mg/day to 30mg/day of oral
prednisolone).
All four patients were discharged from the
hospital, only one of whom required home oxygen
therapy. All four continued to take oral steroids and
showed no evidence of recurrent ILD. After their
episode of ILD, two patients ultimately died of
opportunistic infection 4 months later (no. 1 and
no. 2), one died of progressive lung cancer after
4 months (no. 3) and the remaining one (no. 4) died
of refractory pneumothorax 7 months later.4. Discussion
Before marketing gefitinib, two randomized dou-
ble-blind phase 2 trials (IDEAL 1 and IDEAL 2) had
been conducted, as a result of which the drug was
regarded as a relatively safe agent causing only
mild adverse effects such as an acneiform rash,
diarrhea, and an elevation of liver enzyme amino-
transferases which disappeared after gefitinib
treatment ceased.2,9,13 However, after marketing,
several subsequent reports had warned of pulmon-
ary toxicity, that is, occasionally fatal acute
interstitial pneumonia pathologically diagnosed as
diffuse alveolar damage associated with gefiti-
nib.7,8 Previous reports of adverse effects tendedto classify these events as not related to the drug,
but rather to the progression of primary lung
diseases. Since patients who have been treated
for lung cancer run risks of infection, hemorrhage
from tumor invasion, and a progression of lung
cancer including lymphangitis carcinomatosis, it
appeared difficult to distinguish these conditions
from ILD associated with drugs.
We report here the clinical information, labora-
tory data including pulmonary function tests, and
the BAL fluid analysis of four patients who devel-
oped severe interstitial pneumonia after receiving
gefitinib. Although pre-existing pulmonary fibrosis
has been reported to be one of the important risk
factors for gefitinib-induced ILD,12 we showed that
one patient had prior pulmonary fibrosis pathologi-
cally diagnosed as UIP (patient no. 1), but that the
three others had no prior interstitial lung diseases,
and none had previous thoracic irradiation. There-
fore, we speculate that gefitinib-induced ILD is
induced even in the patients who have no pre-
existing pulmonary fibrosis, although it is still one
of the important risk factors.
As indicated by our report and others, the period
of time from starting gefitinib to the onset of
interstitial pneumonia was short (within 1 week to
1 month, median 15 days in our patients).12
Therefore, we suggested that a careful and close
observation of a chest imaging study and a
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required when starting gefitinib.
Chest imaging study, especially HRCT, has proven
useful in detecting ILD. HRCT in our patients
revealed a bilateral ground-glass attenuation and/
or diffuse alveolar consolidation of the lungs. When
these HRCT findings are detected, we would
recommend performing a bronchoscopy to rule
out lymphangitis carcinomatosis or infections. We
performed BAL in all cases of gefitinib-induced ILD.
However, a total cell count, cell differentiation,
CD4/CD8 ratio, and DLST in BAL fluid did not reveal
the diagnostic characteristics of gefitinib-induced
ILD.
A previous report suggested that gefitinib aug-
mented bleomycin-induced pulmonary fibrosis by
reducing regenerative epithelial proliferation.14 In
contrast, another report showed that the inhibition
of epidermal growth factor receptor tyrosine kinase
reduced pulmonary fibrosis in an animal model.15
Nevertheless, the precise mechanisms of intersti-
tial pneumonia related to gefitinib remain un-
known. We measured the concentrations of IP-10
and TARC in BAL fluid of our four patients. IP-10 is
known as one of the interferon-g inducible chemo-
kines, and as a T-cell chemoattractant possessing
angiostatic properties. IP-10 also contributes to the
development of T helper 1 (Th1)-mediated inflam-
matory responses and lung injury and alters
pulmonary vascular development.16 Although a
previous report showed that IP-10 levels were
lower in tissue specimens from IPF patients than
those from normal controls,17 IP-10 was strongly
detected in an animal model of adult respiratory
distress syndrome.18 We detected high levels of IP-
10 in BAL fluid obtained from all our patients. Taken
together, these findings suggest that a Th1 type of
lung tissue inflammation or lung injury may be
involved as one of the mechanisms of gefitinib-
induced pulmonary toxicity. Further study will be
required to define the role of IP-10 in acute lung
injury.
TARC is recognized as one of the T helper 2 (Th2)-
type chemokines that induces the selective migra-
tion of Th2 cells to the sites of inflammation, and
that enables the recruitment CCR-4-expressing Th2
cells.19 A previous report demonstrated that TARC
in BAL fluid was elevated in cases of eosinophilic
pneumonia, including acute eosinophilic pneumo-
nia, chronic eosinophilic pneumonia, and
drug-induced eosinophilic pneumonia, but not in
idiopathic pulmonary fibrosis or hypersensitivity
pneumonitis.20 One patient (no. 3) in our series
showed an elevation of TARC in his BAL fluid. We
speculated that a drug allergy type lung injury or a
Th2-type lung tissue inflammation might be in-volved in part, although neither one is a major
mechanism governing gefitinib-induced pulmonary
toxicity.
Recently, three cases of postmortem histopathol-
ogy of lung tissues from the patients with gefitinib-
induced ILD have been reported,8,9 and they
showed a pattern of diffuse alveolar damage. Taken
together, we speculated that several different
types of lung injury might be involved in the
mechanisms of gefitinib-induced ILD.
Inoue et al.8 reported four cases of gefitinib-
induced acute interstitial pneumonia, two in which
patients responded to steroids, whereas the others
died of respiratory failure. In our report, all four
patients were treated with high-dose steroids and
responded. High-dose corticosteroids might be
effective in addition to terminating gefitinib treat-
ment. Although the ground-glass opacity in HRCT
was reduced after starting high-dose corticoster-
oids, pulmonary fibrosing, including interstitial
septal thickening, honeycombing, and bronchiec-
tasis, appeared for the first time and persisted. A
restrictive impairment of pulmonary function re-
mained, and DLCO persisted at a low level.
The reason why the incidence of gefitinib-
induced ILD is high in Japan compared with other
countries is not known. Recent reports showed that
the ATP-binding cassette transporter ABCG2 (breast
cancer resistance protein), which is an efflux
protein that plays a role in host detoxification of
various xenobiotic substrates, displays a high
affinity interaction with gefitinib and actively
pumps it out from the cells.21 Therefore, variable
expression and polymorphisms of ABCG2 may
modify the absorption and tissue distribution, and
affect the toxicities. Further, ethnic differences in
allele frequency have been reported for ABCG2
gene polymorphisms.22 Genetic differences such as
the polymorphisms of transporter genes and drug
metabolizing enzyme genes might be the reasons
for this divergence in the incidence of gefitinib-
induced ILD.
The frequency of gefitinib-induced ILD in our
series was low compared with previous reports.10–12
To avoid the overestimation of the diagnosis of
gefitinib-induced ILD, we defined the relatively
strict criteria. As a result, only four cases, who
underwent fiberoptic bronchoscopy and BAL, met
the criteria. This might be the reason for the low
frequency of gefitinib-induced ILD in our series.
In conclusion, we reported the clinical informa-
tion and BAL fluid analysis obtained from four cases
of gefitinib-induced ILD. We proposed the careful
and close observation by a chest imaging study and
a collection of respiratory symptoms when starting
gefitinib. Although withdrawing gefitinib and ad-
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the patients’ conditions in our cases, further
evaluation would be required. At the present time,
not only the mechanisms behind gefitinib-induced
ILD but also its clinical diagnostic criteria have not
been established. Our present data may provide
some clues for a future investigation and analysis of
the disease.References
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